JP2024507996A5 - - Google Patents
Info
- Publication number
- JP2024507996A5 JP2024507996A5 JP2023552220A JP2023552220A JP2024507996A5 JP 2024507996 A5 JP2024507996 A5 JP 2024507996A5 JP 2023552220 A JP2023552220 A JP 2023552220A JP 2023552220 A JP2023552220 A JP 2023552220A JP 2024507996 A5 JP2024507996 A5 JP 2024507996A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- plasmid
- seq
- cells
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163154639P | 2021-02-26 | 2021-02-26 | |
| US63/154,639 | 2021-02-26 | ||
| PCT/US2022/018027 WO2022183072A1 (en) | 2021-02-26 | 2022-02-25 | Lymphocyte targeted lentiviral vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507996A JP2024507996A (ja) | 2024-02-21 |
| JP2024507996A5 true JP2024507996A5 (https=) | 2025-03-03 |
Family
ID=80780729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023552220A Pending JP2024507996A (ja) | 2021-02-26 | 2022-02-25 | リンパ球を標的とするレンチウイルスベクター |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20240218390A1 (https=) |
| EP (1) | EP4298114A1 (https=) |
| JP (1) | JP2024507996A (https=) |
| KR (1) | KR20230160242A (https=) |
| CN (1) | CN117203223A (https=) |
| AU (1) | AU2022227021A1 (https=) |
| BR (1) | BR112023017213A2 (https=) |
| CA (1) | CA3212006A1 (https=) |
| IL (1) | IL305411A (https=) |
| MX (1) | MX2023009910A (https=) |
| WO (1) | WO2022183072A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022227021A1 (en) | 2021-02-26 | 2023-09-21 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
| US12565647B2 (en) | 2021-05-28 | 2026-03-03 | The Regents Of The University Of California | Compositions and methods for targeted delivery of CRISPR-Cas effector polypeptides and transgenes |
| IL313473A (en) | 2021-12-15 | 2024-08-01 | Interius Biotherapeutics Inc | Pseudotyped viral particles, compositions comprising the same, and uses thereof |
| KR20250057777A (ko) | 2022-07-25 | 2025-04-29 | 인테리우스 바이오테라퓨틱스, 인코포레이티드 | 돌연변이된 폴리펩티드, 이를 포함하는 조성물, 및 그 용도(mutated polypeptides, compositions comprising the same, and uses thereof) |
| EP4587580A2 (en) * | 2022-09-12 | 2025-07-23 | The Board of Trustees of the Leland Stanford Junior University | Composition and method of universal pseudotyped retroviruses |
| CN117802163A (zh) * | 2022-09-30 | 2024-04-02 | 深圳市济因生物科技有限公司 | 靶向载体及其制备方法与用途 |
| KR20250121163A (ko) * | 2022-11-04 | 2025-08-11 | 우모자 바이오파마 인코포레이티드 | 융합 분자를 디스플레이하는 렌티바이러스 입자 및 이의 용도 |
| TW202434735A (zh) * | 2022-11-04 | 2024-09-01 | 美商烏莫賈生物製藥股份有限公司 | 展示黏著分子融合的顆粒 |
| WO2024145593A1 (en) * | 2022-12-29 | 2024-07-04 | Kelonia Therapeutics, Inc. | Recombinant retrovirus, compositions, and methods of use |
| WO2024145605A1 (en) * | 2022-12-29 | 2024-07-04 | Kelonia Therapeutics, Inc. | Recombinant retroviruses, compositions, and methods of use |
| WO2024145599A1 (en) * | 2022-12-29 | 2024-07-04 | Kelonia Therapeutics, Inc. | Recombinant retrovirus, compositions, and methods of use |
| WO2024145622A1 (en) * | 2022-12-29 | 2024-07-04 | Kelonia Therapeutics, Inc. | Recombinant retroviruses, compositions, and methods of use |
| EP4680753A2 (en) * | 2023-03-17 | 2026-01-21 | Kelonia Therapeutics, Inc. | Dual targeted gene therapy |
| WO2024207008A2 (en) * | 2023-03-30 | 2024-10-03 | Kelonia Therapeutics, Inc. | In vivo lentivirus animal models |
| JP2026512079A (ja) * | 2023-04-10 | 2026-04-14 | 深▲せん▼市済因生物科技有限公司 | 突然変異型の水疱性口内炎ウイルスｇ糖タンパク及びターゲティングベクター |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| EP4713467A1 (en) * | 2023-05-15 | 2026-03-25 | Umoja Biopharma, Inc. | Lentiviral delivery of anti-cd20 chimeric antigen receptors |
| ES3055997T3 (en) * | 2023-06-30 | 2026-02-17 | Esobiotec Sa | Viral vector and producer cell |
| WO2025011662A1 (zh) * | 2023-07-12 | 2025-01-16 | 深圳市济因生物科技有限公司 | 一种载体和体外转染非激活t细胞的方法 |
| CN121443745A (zh) * | 2023-07-25 | 2026-01-30 | 深圳市济因生物科技有限公司 | 一种病毒载体及tcr亚基的应用 |
| CN121844055A (zh) * | 2023-08-16 | 2026-04-10 | 深圳市济因生物科技有限公司 | 一种病毒载体及其在感染b细胞中的应用 |
| WO2025072257A1 (en) * | 2023-09-25 | 2025-04-03 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| AU2024353718A1 (en) | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| AU2024353243A1 (en) | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Antigen binding polypeptides |
| CN116987157B (zh) * | 2023-09-27 | 2023-11-28 | 深圳华大生命科学研究院 | 一种弹状病毒包膜蛋白、含其的靶向慢病毒载体及其应用 |
| WO2025149068A1 (zh) * | 2024-01-10 | 2025-07-17 | 深圳市济因生物科技有限公司 | 一种病毒颗粒及其制备方法与应用 |
| WO2025178803A1 (en) * | 2024-02-21 | 2025-08-28 | The Regents Of The University Of California | Compositions and methods for targeted delivery of nucleic acid-binding effector polypeptides |
| WO2025203091A2 (en) * | 2024-03-26 | 2025-10-02 | Micro Crispr Pvt. Ltd. | Surface modification of lentiviral particle and producer cell thereof |
| CN119174831A (zh) * | 2024-11-26 | 2024-12-24 | 中国医学科学院医学实验动物研究所 | 基于冠状病毒Spike与hACE2互作介导的细胞特异性基因递送系统 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| TW225528B (https=) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| CA2258548C (en) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| EP0954315A2 (en) | 1996-09-13 | 1999-11-10 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| ATE528406T1 (de) | 1999-04-29 | 2011-10-15 | Gbp Ip Llc | Verfahren und mittel zur herstellung von sicheren,rekombinanten lentivirusvektoren mit hohem titer |
| IL148621A0 (en) | 1999-09-17 | 2002-09-12 | Pro Virus Inc | Oncolytic virus |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| CA2344208A1 (en) | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Method |
| PT1478648E (pt) | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| DE60333487D1 (de) | 2002-12-13 | 2010-09-02 | Genetix Pharmaceuticals Inc | Therapeutische retrovirus-vektoren für gentherapie |
| US20080227736A1 (en) | 2004-06-03 | 2008-09-18 | Regents Of The University Of California, | Targeting Pseudotyped Retroviral Vectors |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| EP1885186B1 (en) | 2005-06-01 | 2015-09-02 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US8008268B2 (en) | 2006-07-25 | 2011-08-30 | Merial Limited | Vaccines against vesicular stomatitis |
| EP1975239A1 (en) | 2006-09-27 | 2008-10-01 | Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer | Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening |
| EP2019144A1 (en) | 2007-07-23 | 2009-01-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vector particles for targeting CD34+ cells |
| EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| AU2009266924B2 (en) | 2008-07-01 | 2015-12-10 | Genocea Biosciences, Inc. | Antigen screening system |
| CA2825370A1 (en) | 2010-12-22 | 2012-06-28 | President And Fellows Of Harvard College | Continuous directed evolution |
| WO2014016383A2 (en) | 2012-07-25 | 2014-01-30 | Theravectys | Glycoproteins for pseudotyping lentivectors |
| BR122020002986A8 (pt) | 2012-08-20 | 2023-04-18 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Método e composições para imunoterapia celular |
| US10072273B2 (en) | 2014-01-10 | 2018-09-11 | Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Pseudotyped lentiviral vectors |
| SG11201605632SA (en) | 2014-01-21 | 2016-08-30 | Einstein Coll Med | Cellular platform for rapid and comprehensive t-cell immunomonitoring |
| JP6509884B2 (ja) | 2014-01-30 | 2019-05-08 | チルドレンズ ホスピタル メディカル センター | 鎌状赤血球病の遺伝子的是正のための改善された胎児ヘモグロビン |
| US10816554B2 (en) | 2014-04-04 | 2020-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand discovery for T cell receptors |
| HUE049514T2 (hu) | 2014-04-25 | 2020-09-28 | Bluebird Bio Inc | Javított eljárások adoptív sejtterápiák kialakítására |
| US9759689B2 (en) | 2014-05-02 | 2017-09-12 | The Regents Of The University Of Michigan | Real-time detection and imaging of terahertz pulse radiation by using photoacoustic conversion |
| EP3031923A1 (en) | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
| PL3560953T3 (pl) * | 2014-12-24 | 2024-05-13 | Autolus Limited | Komórka |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| CN111093715A (zh) | 2017-09-18 | 2020-05-01 | 儿童医院医疗中心 | 强绝缘子和其在基因递送中的用途 |
| GB201715052D0 (en) * | 2017-09-19 | 2017-11-01 | Oxford Genetics Ltd | Vectors |
| JP7799945B2 (ja) | 2017-09-22 | 2026-01-16 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック | 変異型ウイルスタンパク質 |
| JP7599205B2 (ja) * | 2018-06-01 | 2024-12-13 | アンヘレス セラピューティクス インコーポレイテッド | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 |
| US20240025963A1 (en) | 2018-12-14 | 2024-01-25 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| CN114072418A (zh) | 2019-05-20 | 2022-02-18 | 实验与技术生物学研究所(Ibet) | 逆转录病毒科病毒载体伪分型的改性包膜糖蛋白及其获得方法 |
| JP7658584B2 (ja) | 2019-05-23 | 2025-04-08 | マサチューセッツ インスティテュート オブ テクノロジー | リガンドの発見およびレトロウイルス表面ディスプレーを介した遺伝子送達 |
| AU2022227021A1 (en) | 2021-02-26 | 2023-09-21 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
| JP2024513973A (ja) | 2021-04-16 | 2024-03-27 | マサチューセッツ インスティテュート オブ テクノロジー | 造血幹細胞のウイルスによる標的化 |
| IL313473A (en) | 2021-12-15 | 2024-08-01 | Interius Biotherapeutics Inc | Pseudotyped viral particles, compositions comprising the same, and uses thereof |
-
2022
- 2022-02-25 AU AU2022227021A patent/AU2022227021A1/en active Pending
- 2022-02-25 IL IL305411A patent/IL305411A/en unknown
- 2022-02-25 EP EP22710865.1A patent/EP4298114A1/en active Pending
- 2022-02-25 BR BR112023017213A patent/BR112023017213A2/pt unknown
- 2022-02-25 MX MX2023009910A patent/MX2023009910A/es unknown
- 2022-02-25 US US18/279,201 patent/US20240218390A1/en active Pending
- 2022-02-25 JP JP2023552220A patent/JP2024507996A/ja active Pending
- 2022-02-25 KR KR1020237030416A patent/KR20230160242A/ko active Pending
- 2022-02-25 CA CA3212006A patent/CA3212006A1/en active Pending
- 2022-02-25 CN CN202280028023.6A patent/CN117203223A/zh active Pending
- 2022-02-25 WO PCT/US2022/018027 patent/WO2022183072A1/en not_active Ceased
-
2023
- 2023-10-02 US US18/375,868 patent/US12312593B2/en active Active
-
2025
- 2025-05-22 US US19/215,495 patent/US20250277238A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024507996A5 (https=) | ||
| AU2019299439B2 (en) | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof | |
| US20240425565A1 (en) | Chimeric Natural Killer Cell Receptors and Method of Using Thereof | |
| JP7699154B2 (ja) | 腫瘍微小環境を逆転させる融合タンパク質及びその使用 | |
| EP2884999B1 (en) | Method and compositions for cellular immunotherapy | |
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| JP2020506700A5 (https=) | ||
| JP2021532742A5 (https=) | ||
| US11760806B2 (en) | CD-38 directed chimeric antigen receptor constructs | |
| JP2023527530A (ja) | 同種異系移植のための操作された免疫細胞 | |
| JP7723420B2 (ja) | Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤 | |
| JP2021514631A5 (https=) | ||
| US20210261646A1 (en) | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof | |
| CA3150401A1 (en) | Nef-containing t cells and methods of producing thereof | |
| JP2024525815A5 (https=) | ||
| US12534509B2 (en) | Engineered immune cells with receptor cross-talk | |
| JP2025536940A (ja) | 新規ｃｄ１９バインダー、それを含むｃａｒ－ｔ構造体、およびその使用方法 | |
| CN117683139A (zh) | 组成型嵌合细胞因子受体及表达其的免疫细胞及应用 | |
| KR20250089526A (ko) | Il18과 조합된 신규한 cd19 결합제를 포함하는 car-t 작제물 및 이의 사용 방법 | |
| WO2025218739A1 (en) | Polypeptide systems | |
| EA050762B1 (ru) | Аллогенные терапевтические клетки | |
| WO2025191154A1 (en) | Therapeutic agents | |
| WO2023014633A2 (en) | Vector systems for delivery of two polynucleotides and methods of making and using same | |
| HK1212205B (en) | Method and compositions for cellular immunotherapy |